同源康医药-B（02410）近日发布公告称，公司董事会拟于2026年6月23日召开年度股东大会，审议并授权董事会于相关期间内回购不超过已发行H股总数10%的股份。根据公告，截至最后可行日期，公司已发行H股总数约为380,065,818股，若授权获批，最多可回购38,006,581股。
公告显示，此次购回资金将依据上市规则及相关法律法规，从公司合法可用的内部资源中支付。公司方面认为，进行股份购回有助于维护公司价值及保障股东权益，董事会认为此举符合公司及全体股东的整体利益。按照议程安排，该回购计划仍需获得本次年度股东大会通过。
据公告介绍，公司同期将于2026年6月17日至6月23日暂时关闭H股股东名册，所有在此期间登记在册的股东均可出席大会并表决。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.